Cat. No.: HY-13635

Finasteride

(Synonyms: MK-906)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.

For research use only. We do not sell to patients.

Purity: 99.97%
CAS No.: 98319-26-7
Formula: C₂₃H₃₆N₂O₂
Molecular Weight:372.54

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Finasteride Chemical Structure

CAS No.: 98319-26-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 4.2 nM (type II 5α-reductase)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	911 nM Compound: Finasteride	Compound was evaluated for the inhibition of human Steroid 5-alpha-reductase type 1 from recombinant CHO cells Compound was evaluated for the inhibition of human Steroid 5-alpha-reductase type 1 from recombinant CHO cells	[PMID: 9873639]
DU-145	IC₅₀	0.04 μM Compound: Finasteride	Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type I in human DU-145 cell assay at 5 nM of androstenedione Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type I in human DU-145 cell assay at 5 nM of androstenedione	[PMID: 11063622]
DU-145	IC₅₀	60 nM Compound: Finasteride	Inhibition of [1-beta-3H]-androstenedione binding to human steroid 5-alpha-reductase type I expressed in DU-145 cells at 10 uM Inhibition of [1-beta-3H]-androstenedione binding to human steroid 5-alpha-reductase type I expressed in DU-145 cells at 10 uM	[PMID: 15828836]
DU-145	IC₅₀	3.9 μM Compound: Finasteride	Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 20171759]
DU-145	IC₅₀	548 μM Compound: Finasteride	Cytotoxicity against human DU145 cells by rapid colorimetric assay Cytotoxicity against human DU145 cells by rapid colorimetric assay	[PMID: 26780831]
DU-145	IC₅₀	13.53 μM Compound: Finasteride	Cytotoxicity against human DU145 cells assessed as growth inhibition after 24 hrs by CCK8 assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 24 hrs by CCK8 assay	[PMID: 29615343]
DU-145	IC₅₀	14.53 μM Compound: Finasteride	Antiproliferative activity against human DU145 cells after 24 hrs by CCK-8 assay Antiproliferative activity against human DU145 cells after 24 hrs by CCK-8 assay	[PMID: 30482547]
DU-145	IC₅₀	26.3 nM Compound: MK-906	In vitro inhibition of human steroid 5-alpha-reductase type I in Du-145 cells In vitro inhibition of human steroid 5-alpha-reductase type I in Du-145 cells	[PMID: 7707319]
DU-145	IC₅₀	42 nM Compound: Finasteride	Inhibitory activity against human 5-alpha Reductase-1 expressed in DU-145 cells Inhibitory activity against human 5-alpha Reductase-1 expressed in DU-145 cells	[PMID: 9089333]
DU-145	IC₅₀	3.9 μM Compound: Finasteride	Cytotoxicity against Homo sapiens (human) DU145 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) DU145 cells after 48 hr by MTT assay	10.1007/s00044-010-9393-3
Fibroblast	IC₅₀	62 nM Compound: 1	Compound was tested for inhibition of Type I 5-alpha-reductase in Human genital skin (Hs68) foreskin fibroblast cells. Compound was tested for inhibition of Type I 5-alpha-reductase in Human genital skin (Hs68) foreskin fibroblast cells.	[PMID: 8381185]
HEK293	IC₅₀	0.06 μM Compound: Finasteride	Inhibition of Human steroid 5-alpha-reductase type II expressed in HEK293 cells Inhibition of Human steroid 5-alpha-reductase type II expressed in HEK293 cells	[PMID: 11063622]
HEK293	IC₅₀	0.54 μM Compound: Finasteride	Inhibition of Human steroid 5-alpha-reductase type I expressed in HEK293 cells Inhibition of Human steroid 5-alpha-reductase type I expressed in HEK293 cells	[PMID: 11063622]
HEK293	IC₅₀	25 nM Compound: 9f	Inhibition of steroid 5-alpha reductase type 2 expressed in HEK 293 cells Inhibition of steroid 5-alpha reductase type 2 expressed in HEK 293 cells	[PMID: 17490876]
HEK293	IC₅₀	453 nM Compound: 9f	Inhibition of steroid 5-alpha reductase type 1 expressed in HEK 293 cells Inhibition of steroid 5-alpha reductase type 1 expressed in HEK 293 cells	[PMID: 17490876]
HEK293	IC₅₀	30.3 nM Compound: 3	Inhibition of human type-2 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis Inhibition of human type-2 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis	[PMID: 22776417]
HEK293	IC₅₀	453 nM Compound: 3	Inhibition of human type-1 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis Inhibition of human type-1 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis	[PMID: 22776417]
HEK293	IC₅₀	40 nM Compound: Finasteride	Inhibition of human 5alpha-2 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis Inhibition of human 5alpha-2 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis	[PMID: 26780831]
HEK293	IC₅₀	453 nM Compound: Finasteride	Inhibition of human 5alpha-1 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis Inhibition of human 5alpha-1 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis	[PMID: 26780831]
HEK293	IC₅₀	>50 μM Compound: 1	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	[PMID: 28693914]
HEK293	IC₅₀	1.2 nM Compound: 18	Inhibition of human type 2 5alpha reductase expressed in HEK293 cells Inhibition of human type 2 5alpha reductase expressed in HEK293 cells	[PMID: 29400967]
HEK293	IC₅₀	650 nM Compound: 18	Inhibition of human type 1 5alpha reductase expressed in HEK293 cells Inhibition of human type 1 5alpha reductase expressed in HEK293 cells	[PMID: 29400967]
HEK293	IC₅₀	218 nM Compound: 2a	In vitro inhibition of human Steroid 5-alpha-reductase type I in transfected 293 cells using [3H]- delta4-Androstenedione as substrate In vitro inhibition of human Steroid 5-alpha-reductase type I in transfected 293 cells using [3H]- delta4-Androstenedione as substrate	[PMID: 7739004]
LNCaP	IC₅₀	19.8 μg/mL Compound: Finasteride	Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line) Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line)	[PMID: 11527731]
LNCaP	IC₅₀	53 μM Compound: Finasteride	Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line) Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line)	[PMID: 11527731]
LNCaP	IC₅₀	14.53 μM Compound: Finasteride	Cytotoxicity against human LNCAP cells assessed as growth inhibition after 24 hrs by CCK8 assay Cytotoxicity against human LNCAP cells assessed as growth inhibition after 24 hrs by CCK8 assay	[PMID: 29615343]
LNCaP	IC₅₀	13.53 μM Compound: Finasteride	Antiproliferative activity against human LNCAP cells after 24 hrs by CCK-8 assay Antiproliferative activity against human LNCAP cells after 24 hrs by CCK-8 assay	[PMID: 30482547]
LNCaP	IC₅₀	0.76 μM Compound: Finasteride	Inhibition of steroid 5-alpha-reductase in human LNCAP cells assessed as reduction in 5- dihydrotestosterone formation incubated for 60 mins by LC-MS analysis Inhibition of steroid 5-alpha-reductase in human LNCAP cells assessed as reduction in 5- dihydrotestosterone formation incubated for 60 mins by LC-MS analysis	[PMID: 32040314]
Macrophage	IC₅₀	28.2 μM Compound: Finasteride	Cytotoxicity against Balb/C mouse macrophages assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against Balb/C mouse macrophages assessed as cell viability after 24 hrs by MTT assay	[PMID: 20171759]
MCF7	IC₅₀	44.14 μM Compound: 1	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 28693914]
MDA-MB-231	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 28693914]
PC-3	IC₅₀	>80 μM Compound: 1	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28757062]
PC-3	IC₅₀	17.83 μM Compound: Finasteride	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by CCK8 assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by CCK8 assay	[PMID: 29615343]
PC-3	IC₅₀	17.8 μM Compound: Finasteride	Antiproliferative activity against human PC3 cells after 24 hrs by CCK-8 assay Antiproliferative activity against human PC3 cells after 24 hrs by CCK-8 assay	[PMID: 30482547]
PC-3	IC₅₀	17.8 μM Compound: Finasteride	Antiproliferative activity against AR-deficient human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Antiproliferative activity against AR-deficient human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 31493989]

In Vitro

Finasteride (10 μM; 6-24 h) induces the expression of HO-1 and Nrf2 proteins in PC-3 cells^[2].
Finasteride decreases the conversion of [³H]testosterone (T) to [³H]dihydrotestosterone (DHT) in P. crustosum^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

PC-3, DU-145, and LNCaP cells
Concentration:

10 μM
Incubation Time:

6, 12, 24 h
Result:

Increased the expression of HO-1 protein in a time-dependent manner in PC-3 cells.
Induced the expression of Nrf2 protein in DU-145 and PC-3 cells, but not in LNCaP cells.

In Vivo

Finasteride (0.1-0.5 mg/kg; p.o. once daily for 16 weeks) reduces prostatic size in dogs with BPH without adversely affecting semen quality or serum testosterone concentration^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male dogs with spontaneous BPH (2.7-11 years old; 10.3-49 kg)^[3]
Dosage:

0.1-0.5 mg/kg
Administration:

P.o. once daily for 16 weeks
Result:

Decreased prostatic diameter (20%), prostatic volume (43%), and serum DHT concentration (58%).
Decreased semen volume but did not adversely effect on semen quality or serum testosterone concentration.
No adverse effects on dogs.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 98319-26-7
Appearance Solid
Molecular Weight 372.54
Formula C₂₃H₃₆N₂O₂
Color White to off-white
SMILES

O=C([C@H]1CC[C@]2([H])[C@]1(C)CC[C@]3([H])[C@@]4(C)C=CC(N[C@]4([H])CC[C@]32[H])=O)NC(C)(C)C
Synonyms

MK-906
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All In Vivo Efficacy StudyWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Phytomedicine

Bushen Tongluo formula ameliorated testosterone propionate-induced benign prostatic hyperplasia in rats. [Abstract]

2023 Nov:120:155048. PMID: 37651753

Finasteride purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155048. [Abstract]

Finasteride (Proscar) (0.5 mg/kg; i.g.; once daily for 28 d) significantly decreased the prostate volume, wet weight, and prostate index of TP-induced BPH rats.

Finasteride purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155048. [Abstract]

Protein levels of TGF-β1, vimentin, and E-cadherin were detected by western blot analysis. Finasteride (Proscar) (0.5 mg/kg; i.g.; once daily for 28 d) significantly decreased TGF-β1 expression in the prostate tissues of BPH rats.

Finasteride purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155048. [Abstract]

Finasteride (Proscar) (0.5 mg/kg; i.g.; once daily for 28 d)-spiked serum significantly inhibited the activities of BPH-1 cells at 48, 72, and 96 h compared to the serum of the model group.
J Transl Med

The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling. [Abstract]

2023 Feb 2;21(1):71. PMID: 36732752

Finasteride purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Feb 2;21(1):71. [Abstract]

Finasteride (Fina) (10 mg/kg; p.o.; once daily for 7 d) attenuated the analgesic effects of TPPU in anhedonia-susceptible mice.

Finasteride purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Feb 2;21(1):71. [Abstract]

TSPO antagonist Finasteride (Fina) (10 mg/kg; p.o.; once daily for 7 d) attenuated the antidepressant effects of TPPU in anhedonia-susceptible mice.
J Pain

Alleviation of Mechanical Allodynia by 14,15-Epoxyeicosatrienoic Acid in a Central Poststroke Pain Model: Possible Role of Allopregnanolone and δ-Subunit-Containing Gamma-Aminobutyric Acid A Receptors. [Abstract]

2019 May;20(5):577-591. PMID: 30500366
Sci Rep

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase. [Abstract]

2019 Dec 23;9(1):19703. PMID: 31873149

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (268.43 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6843 mL

13.4214 mL

26.8428 mL

5 mM

0.5369 mL

2.6843 mL

5.3686 mL

10 mM

0.2684 mL

1.3421 mL

2.6843 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 2 mg/mL (5.37 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Flores E, et, al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003 May;3(3):225-37. [Content Brief]

[2]. Yun DK, et, al. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul). 2013 Jan;21(1):49-53. [Content Brief]

[3]. Sirinarumitr K, et, al. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218(8):1275-80. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6843 mL	13.4214 mL	26.8428 mL	67.1069 mL
	5 mM	0.5369 mL	2.6843 mL	5.3686 mL	13.4214 mL
	10 mM	0.2684 mL	1.3421 mL	2.6843 mL	6.7107 mL
	15 mM	0.1790 mL	0.8948 mL	1.7895 mL	4.4738 mL
	20 mM	0.1342 mL	0.6711 mL	1.3421 mL	3.3553 mL
	25 mM	0.1074 mL	0.5369 mL	1.0737 mL	2.6843 mL
	30 mM	0.0895 mL	0.4474 mL	0.8948 mL	2.2369 mL
	40 mM	0.0671 mL	0.3355 mL	0.6711 mL	1.6777 mL
	50 mM	0.0537 mL	0.2684 mL	0.5369 mL	1.3421 mL
	60 mM	0.0447 mL	0.2237 mL	0.4474 mL	1.1184 mL
	80 mM	0.0336 mL	0.1678 mL	0.3355 mL	0.8388 mL
	100 mM	0.0268 mL	0.1342 mL	0.2684 mL	0.6711 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Finasteride

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Lipid Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Environmental Pollutant Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Finasteride

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Finasteride

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Lipid Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Environmental Pollutant Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Finasteride

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Finasteride Related Classifications

Cat. No.: HY-13635